



Company announcement 11-2019

Birkerød, Denmark and Hilden, Germany, 27 August 2019

## **ViroGates and QIAGEN announces a partnership to launch suPARnostic® Quick Triage on QIAGEN's automated Lateral Flow (aLF) platform**

ViroGates A/S (Nasdaq First North Denmark: VIRO), who delivers blood test systems, primarily for emergency departments in hospitals, today announces that it has entered into a distribution and license agreement with QIAGEN under which ViroGates will act as an appointed distributor for QIAGEN of the aLF reader (<https://www.alf-reader.com/alf-concept/>). ViroGates has completed a validation of the instrument for the suPARnostic® Quick Triage product, and the reader can be used as a CE-IVD approved instrument for the suPARnostic® Quick Triage product.

ViroGates' suPARnostic® Quick Triage product will benefit from existing aLF reader placements and being included in the test menu for the aLF reader, as well as shared marketing efforts. The aLF reader also provides additional benefits to hospitals as it incorporates a bar code scanner, push-solutions for the software required for running the suPARnostic® Quick Triage as well as automated integration into hospital laboratory management software among many other features.

**CEO Jakob Knudsen, says in a comment:** *"ViroGates is proud to announce this collaboration with QIAGEN, leading global provider of Sample to Insight solutions and leader in the field of Near Patient Testing solutions. This step marks an even closer collaboration with QIAGEN and also a much better product offering for our clinical customers at the hospitals who can now run several tests on the reader and enjoy a much simpler integration with its existing lab information systems. The suPARnostic® software solutions will be available to customers on the aLF readers shortly and we expect a significant pull effect from this in the marketplace."*

*"The unique business approach we follow with the aLF rapid test reader allows end users to perform a range of different tests at the point of care."* **comments Micheal Doumanas, Director Strategic Alliances at QIAGEN.** *"We are pleased that Virogates joins the aLF family with their innovative suPARnostic® Quick Triage test and that we are jointly able to improve the lives of patients even further – through fast diagnostics at the point of care."*

### **For further information contact:**

CEO Jakob Knudsen

Tel. (+45) 2113 1336, Email: [jk@virogates.com](mailto:jk@virogates.com)

### **ViroGates A/S**

CVR-nr. 25734033, Blokken 45, DK-340 Birkerød

[www.virogates.com](http://www.virogates.com)

### **QIAGEN**

Public Relations

Robert Reitze +49 2103 29 11676

e-mail: [pr@QIAGEN.com](mailto:pr@QIAGEN.com)

### **Certified Advisor for ViroGates A/S**

Västra Hamnen Corporate Finance

Per Lönn

Tel. (+46) 40 200 250, Email: [per.lonn@vhcorp.se](mailto:per.lonn@vhcorp.se)

### **About ViroGates**

ViroGates is an international Medtech company headquartered in Denmark. ViroGates develops and sells prognostic products to the healthcare sector. The products are used in hospital emergency services, in particular to make a clinical decision on hospitalization or discharge of emergency patients, which can lead to better clinical decisions, faster discharge and optimization of healthcare resources. The products can also be used for the prognosis of lifestyle-related diseases such as cardiovascular disease, type 2 diabetes, cancer, etc. The ViroGates test suPARnostic® measures the suPAR (Soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream, and with the suPARnostic® Quick Triage and TurbiLatex test, hospital staff will

Blokken 45, 3460 Birkerød, Denmark

[www.virogates.com](http://www.virogates.com)



get answers in just 20 minutes. The prognostic value of suPARnostic® is validated by more than 550 clinical trials and studies which included more than 350,000 blood samples.

#### **About QIAGEN**

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of June 30, 2019, QIAGEN employed approximately 5,200 people in over 35 locations worldwide. Further information can be found at <http://www.qiagen.com>.